多形性胶质母细胞瘤治疗市场规模、份额和成长分析（按治疗方法、药物类别、最终用途和地区划分）—2026-2033年产业预测

预计到 2024 年，多形性胶质母细胞瘤治疗市场规模将达到 29.6 亿美元，到 2025 年将成长至 32.3 亿美元，到 2033 年将成长至 63.8 亿美元，在预测期（2026-2033 年）内复合年增长率为 8.9%。

胶质母细胞瘤治疗市场预计将迎来显着成长，这主要得益于胶质母细胞瘤发生率的上升以及研发投入的增加。各大製药公司强大的产品平臺，加上脑肿瘤发生率的不断攀升，预计将进一步推动市场扩张。统计数据显示，脑部癌症的死亡率和诊断率居高不下，凸显了开发有效治疗方法的迫切性。然而，高昂的治疗费用和有效药物研发的困难等挑战阻碍了治疗进展，尤其是在治疗资源匮乏的发展中地区。儘管如此，个人化医疗的进步和令人鼓舞的临床试验结果，特别是免疫疗法、标靶治疗和创新治疗方法的进展，仍然为市场带来了巨大的机会。

多形性胶质母细胞瘤治疗市场驱动因素

全球胶质母细胞瘤治疗市场的主要驱动因素之一是胶质母细胞瘤（一种高度侵袭性的脑癌）发病率和盛行率的不断上升。随着人们对这种恶性肿瘤的认识不断提高以及诊断技术的进步，越来越多的病例被发现，从而刺激了对有效治疗方案的需求。此外，持续的研发活动正在为包括标靶治疗和免疫疗法在内的新型治疗方法铺平道路。对个人化医疗的日益重视有望改善患者的治疗效果，进一步推动市场成长，并促进胶质母细胞瘤治疗领域的创新。

限制多形性胶质母细胞瘤治疗市场的因素

全球胶质母细胞瘤治疗市场的主要限制因素之一是治疗方法费用高昂，这限制了低收入地区和医疗体系的患者获得治疗的机会。包括标靶治疗和免疫疗法在内的创新疗法的高成本给患者和医疗服务提供者带来了沉重的经济负担，并可能导致治疗效果的差异。此外，胶质母细胞瘤是一种异质性疾病，难以开发出普遍有效的治疗方法。而且，某些治疗方法缺乏健保覆盖也会进一步阻碍患者获得治疗，并抑制这一重要肿瘤领域的市场成长和创新。

多形性胶质母细胞瘤治疗市场趋势

在胶质母细胞瘤（GBM）治疗领域，个人化医疗已成为一个显着趋势，并正在革新治疗方法。基于个别基因谱客製化治疗方案，能够提高介入措施的精准性和有效性，并使医疗服务提供者能够根据肿瘤的特定特征制定治疗方法。基因组监测和生物标记识别技术的进步正在推动这项标靶策略的实施，从而带来更多个人化的治疗选择，改善患者的预后。这种转变不仅增强了肿瘤科医师根据肿瘤生物学独特性优化治疗的能力，也推动了对创新诊断工具和治疗方法的需求，从而塑造了GBM治疗的未来。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析和影响

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 专利分析
• 案例研究

全球多形性胶质母细胞瘤治疗市场规模（按治疗方法和复合年增长率划分）（2026-2033 年）

• 化疗
  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Lomustine
  • 其他的
• 放射治疗
  • 体外放射线治疗（EBRT）
  • 近距离放射
• 标靶治疗
  • 单株抗体
  • 蛋白酪氨酸激酶抑制剂
• 免疫疗法
  • 查核点抑制剂
  • 疫苗疗法
• 肿瘤电场治疗（TTF）
• 外科手术
  • 开颅手术
  • 切片检查

全球多形性胶质母细胞瘤治疗市场规模（按最终用户和复合年增长率划分）（2026-2033 年）

• 医院
• 诊所
• 门诊手术中心
• 研究所

全球多形性胶质母细胞瘤治疗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• Roche Holding AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• Eli Lilly and Company
• AbbVie Inc.
• Sanofi SA
• Bayer AG
• AstraZeneca plc
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc
• Celgene Corporation
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Ipsen SA
• Sumitomo Dainippon Pharma Co., Ltd.
• Karyopharm Therapeutics Inc.

结论与建议

Glioblastoma Multiforme Treatment Market size was valued at USD 2.96 Billion in 2024 and is poised to grow from USD 3.23 Billion in 2025 to USD 6.38 Billion by 2033, growing at a CAGR of 8.9% during the forecast period (2026-2033).

The glioblastoma multiforme treatment market is poised for substantial growth driven by rising glioblastoma prevalence and a heightened emphasis on research and development. A robust product pipeline from leading pharmaceutical firms, alongside a growing incidence of brain tumors, is expected to further propel market expansion. Statistics indicate significant mortality and diagnosis rates for brain-related cancers, underscoring the urgent need for effective therapies. However, challenges such as high treatment costs and the difficulty in developing efficacious drugs impede progress, particularly in developing regions where access to expensive therapies may be limited. Nevertheless, there are considerable opportunities in the market, particularly in advancing immunotherapies, targeted therapies, and innovative treatment combinations, bolstered by advancements in personalized medicine and promising clinical trial outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Glioblastoma Multiforme Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Glioblastoma Multiforme Treatment Market Segments Analysis

Global Glioblastoma Multiforme Treatment Market is segmented by treatment type, end user and region. Based on treatment type, the market is segmented into chemotherapy (temozolomide, bevacizumab, carmustine, lomustine, others), radiation therapy (external beam radiation therapy (EBRT), brachytherapy), targeted therapy (monoclonal antibodies, tyrosine kinase inhibitors),immunotherapy(checkpoint inhibitors, vaccine therapy), tumor treating fields (TTF) therapy and surgery (craniotomy, biopsy). Based on end user, the market is segmented into hospitals, clinics,ambulatory surgical centersand research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Glioblastoma Multiforme Treatment Market

One of the key market drivers for the Global Glioblastoma Multiforme Treatment Market is the rising incidence and prevalence of glioblastoma, a highly aggressive type of brain cancer. As awareness about this malignancy increases and advancements in diagnostic techniques improve, more cases are being detected, leading to higher demand for effective treatment options. Furthermore, ongoing research and development initiatives are paving the way for novel therapies, including targeted treatments and immunotherapies. This growing focus on personalized medicine aims to enhance patient outcomes, further propelling market growth and fostering innovation within the treatment landscape for glioblastoma multiforme.

Restraints in the Glioblastoma Multiforme Treatment Market

One significant market restraint for the global glioblastoma multiforme treatment market is the high cost of therapies and treatments, which can limit accessibility for patients in lower-income regions and healthcare systems. The expensive nature of innovative treatments, including targeted therapies and immunotherapies, poses financial burdens on patients and healthcare providers, potentially leading to disparities in treatment outcomes. Furthermore, the complexity of glioblastoma as a heterogeneous disease makes it challenging to develop universally effective treatments, and the lack of reimbursement for certain therapies may further inhibit patient access, hindering market growth and innovation in this critical area of oncology.

Market Trends of the Glioblastoma Multiforme Treatment Market

The glioblastoma multiforme (GBM) treatment market is witnessing a significant trend towards the adoption of personalized medicine, revolutionizing therapeutic approaches. Tailoring treatments based on individual genetic profiles enhances the precision and efficacy of interventions, enabling healthcare providers to match therapies with specific tumor characteristics. Advances in genomic research and biomarker identification facilitate this targeted strategy, resulting in more specialized treatment options that improve patient outcomes. This shift not only empowers oncologists to optimize therapy based on the biological uniqueness of each patient's tumor but also fosters a growing demand for innovative diagnostic tools and treatments, shaping the future landscape of GBM management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global Glioblastoma Multiforme Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Chemotherapy
  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Lomustine
  • Others
• Radiation Therapy
  • External Beam Radiation Therapy (EBRT)
  • Brachytherapy
• Targeted Therapy
  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitors
• Immunotherapy
  • Checkpoint Inhibitors
  • Vaccine Therapy
• Tumor Treating Fields (TTF) Therapy
• Surgery
  • Craniotomy
  • Biopsy

Global Glioblastoma Multiforme Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Research Institutes

Global Glioblastoma Multiforme Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, End User)
  • US
  • Canada
• Europe (Treatment Type, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation